Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elravie Re2O vs HA skin booster for skin roughness
NCT07155278Phase 4Completed
- Sponsor
- Yonsei University
- Start
- Nov 2024
- Primary completion
- May 2025
- Modality
- Device-based Delivery
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Elravie Re2O in Skin aging (2 arms), sponsored by Yonsei University. Primary endpoints: Nasolabial fold depth at 20 weeks, Under-eye wrinkles at 20 weeks and 4 more. Started Nov 2024; status: completed.
02
Drugs
Elravie Re2O
03
Conditions
Skin aging
Beyond the preview
Go deeper on NCT07155278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07155278.